LONDON, July 13, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in the American Journal of Psychiatry that examines the definition of “psychedelic-assisted psychotherapy” using psilocybin and offers a new way of…

Source

Previous articleDr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine’s Scientific Advisory Board
Next articleReunion Neuroscience Inc. Shareholders Approve Proposed Plan of Arrangement